In this study, two analytical approaches were exploited for the resolution of binary mixtures of ciprofloxacin HCl (CIP) or norfloxacin (NOR) and phenazopyridine HCl (PHZ). In the first approach, the amplitudes of the first derivative of the ratio spectra were measured at 267 or 287 nm for CIP and at 268 or 291 nm for NOR. PHZ could be directly determined in the presence of CIP or NOR at 405 nm. The calibration graphs were rectilinear over the ranges of 1.0-16.0 µg/mL for CIP or NOR and 1.0-10.0 µg/mL for PHZ. In the second approach, an accurate, reliable and environmentally nontoxic micellar liquid chromatographic (MLC) method was developed. A good chromatographic separation was achieved using a 150 mm × 4.6 mm i.d., 5 µm particle size Spherisorb ODS-2 column. Eco-friendly mobile phase containing 0.12 M sodium dodecyl sulphate, 0.3% triethylamine and 6% n-butanol in 0.02 M orthophosphoric acid of pH 3.0 was pumped at a flow rate of 1 mL/min. Time programmed UV-detection was applied to allow sensitive determination of the studied drugs. The analytes were eluted without interferences in <10 min. Methocarbamol was used as an internal standard. The MLC method was found to be rectilinear over the concentration range of 0.5-20.0 μg/mL for CIP, NOR or PHZ. These optimized and validated methods were successfully applied for the simultaneous analysis of the studied drugs in their synthetic mixtures and co-formulated tablets. Moreover, the second method was further extended to the determination of these drugs in human urine with direct injection and without any pretreatment.
Introduction
Ciprofloxacin HCl (CIP) is 1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride ( Figure 1A ) (1) . CIP has a wider spectrum of activity than nalidixic acid and more favourable pharmacokinetics allowing its use in systemic infections. It has been used in the treatment of infections, which include biliary and urinary tract infections, bone and joint infections, ear, nose and throat infections, anthrax and gastro-enteritis. It is also used for surgical infection prophylaxis (2) . Norfloxacin (NOR) chemically is 1-ethyl-6-fluoro-4-oxo-7-( piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid ( Figure 1B ) (1) . Both CIP and NOR are fluoroquinolone antibacterials with similar properties, but NOR is generally less potent in vitro. NOR is used mainly in the treatment of urinary tract infections and for the treatment of gonorrhea (2) . Combination dosage forms of CIP or NOR and PHZ are commonly indicated in the treatment of urinary tract infections.
CIP and NOR are subjects of monographs in each of British Pharmacopoeia (1) and United States Pharmacopoeia (3) . Reviewing the literature revealed that numerous analytical methods were developed for the assay of these fluoroquinolones, either individually or in combination with other drugs. The most recent articles concerning the chromatographic analysis of these drugs include high-performance liquid chromatography (HPLC) (4-7), ultra-performance liquid chromatography (UPLC) (8) and liquid chromatography/mass spectrometry (LC-MS) (9) (10) (11) (12) (13) (14) .
Phenazopyridine HCl (PHZ, Figure 1C ), 2,6-diamino-3-(phenylazo) pyridine monohydrochloride (3) , is an azo dye that exerts an analgesic effect on the mucosa of the urinary tract and is used to provide symptomatic relief of pain and irritability in conditions such as cystitis, prostatitis and urethritis (2) . Regarding PHZ, some chromatographic methods have been reported for its determination. The most recent articles include HPLC (15) (16) (17) , UPLC (18) and LC-MS (19) . PHZ is an official drug in United States Pharmacopoeia (3) .
Commercially, CIP and NOR are marketed together with PHZ in combined tablets in two different ratios of 2.5:1 and 4:1 (w/w), respectively. From searching the literature review, only two analytical methods with lower sensitivity were reported for simultaneous determination of CIP and PHZ in pharmaceuticals, but not in biological fluids (18, 20) . In addition, no analytical method was reported yet for the concomitant determination of NOR and PHZ neither in pharmaceutical preparations nor in biological fluids. Depending on these facts, our concern was to explore reproducible approaches for the assessment of the studied drugs in their tablets and/or human urine without the need of complicated boring steps of the extraction procedure.
Ratio derivative or derivative quotient spectrophotometry was explored by Salinas et al. (21) to resolve overlapped spectra of salicylic and salicyluric acids. Then, Berzas Nevado et al. (22) extended this method to resolve ternary mixtures of salicylaldehyde, 3-hydroxybenzaldehyde and 4-hydroxybenzaldehyde. Various benefits for this technique have been reported. First, the use of standardized spectra as divisors minimizes experimental errors and background noise (23) . The other benefits include easy measurements on separate peaks, higher values of the analytical signals and the lack of need to work only at zero-crossing points. Also, the presence of a lot of maxima and minima in ratio spectra derivative data of the analytes giving an opportunity for the determination of these compounds in the presence of other active compounds and excipients that possibly interfere with the assay (24) .
Recently, interests in the use of micellar mobile phases in reversed phase liquid chromatography have grown. In such a system, complex interactions (electrostatic, hydrophobic and steric) exist between the solute and both the stationary and mobile phase (25) . The proposed micellar liquid chromatography (MLC) represents an attractive alternative to conventional aqueous-organic phases in clinical analysis. Due to existence of micelles, MLC has several unique advantages (26) such as capability of simultaneous separation of hydrophobic and hydrophilic analytes, possibility of simultaneous enhancement of solvent strength, separation selectivity and reproducibility and possibility of direct injection of physiological samples. In addition, micellar mobile phases are non-toxic, non-inflammable, biodegradable and relatively inexpensive, in comparison to aqueous-organic solvents. Thus, MLC is considered to be an interesting technique for "green chemistry" that copes with current concerns about the environment (27) .
MLC has proved to be a useful technique in the analysis of diverse groups of drugs in pharmaceutical preparations and biological fluids using hybrid micellar mobile phase containing sodium dodecyl sulphate (SDS) and an organic modifier (28) (29) (30) (31) .
The present approaches make use of ratio derivative spectrophotometry and MLC for simultaneous determination of CIP or NOR and PHZ in their co-formulated tablets and/or human urine. The methods was validated and the results were statistically compared with the official USP (3) method. From the merits mentioned above for both techniques, it was concluded that the proposed methods are superior for the official USP (3) method in the following points. The common availability of the instrumentation, the simplicity of procedures, speed, precision and accuracy of the technique still make spectrophotometric methods more attractive, economic and simpler, compared with other methods such as chromatography and electrophoresis (32) . Therefore, it will be more convenient to be applied in quality control laboratories. The proposed MLC method benefits from the two main advantages associated with the use of micellar eluents, namely, the use of eco-friendly mobile phase and direct injection of biological fluids with no prior extraction. So, this technique could be successfully applied to the determination of the studied drugs in human urine with direct injection saving effort, time and cost in sample preparation with low toxicity.
Experimental

Instruments
Spectrophotometry
Analysis was carried out on a Halo DB-30 UV-Visible double-beam spectrophotometer (Dynamica Pty Ltd, Australia). The first derivative of the ratio derivative spectra of CIP or NOR was derived using UV Detective software in the wavelength range (240-370) nm after smoothing of ratio spectra and using scaling factor = 1.
HPLC system
Chromatographic separations were performed using a Shimadzu LC-20AD chromatograph (Japan) equipped with a Rheodyne injector valve with a 20-μL loop and a SPD-20A UV detector. Mobile phases were degassed using a DGU-20A5 solvent degasser. CBM-20A Communication Bus Module was used to connect the instrument to a PC. The mobile phase was filtered using a 0.45-µm membrane filter (Millipore, Ireland) and degassed using a Prominence degasser DGU-20A5.
Cellulose acetate syringe filters with 0.45 µm pore size (Gemma, Barcelona, Spain) were used for human urine filtration. A Consort NV P-901 pH-meter (Belgium, Europe) was employed for pH measurements. An ultrasonic bath (model SS 101 H 230, USA) was also used. A vortex mixer (model: VM-300P; Gemmy Industrial Corp., Taiwan) was used for the preparation of human urine samples. A single punch tablet press machine (Erweka, GmbH., Germany) was also employed.
Materials and reagents
All the chemicals used were of analytical reagent grade, and the solvents were of HPLC grade. High purity water was obtained by filtration of distilled water through a 0.45-μm membrane filter (Millipore) and was used throughout the study.
CIP and NOR were kindly provided by Egyptian International Pharmaceutical Industries Company (EIPICO), Cairo, Egypt. Phenazopyridine HCl (PHZ) was obtained from Kahira Pharm. & Chem. Ind. Co., Cairo, Egypt. The purity percentages of CIP, NOR and PHZ were 99.85 ± 0.90, 100.03 ± 0.75 and 100.20% ± 0.99, respectively, as determined by applying the official USP method (3).
The following pharmaceutical preparations were purchased from commercial sources in the local pharmacy: rately weighed quantity (equivalent to 100.0 mg PHZ) of the mixed contents of 10 powdered Urisept ® tablets to make a homogenous powder mixture, and then, the powder mixture was compressed using the single punch press machine.
Methocarbamol (MTC, Sigma Pharmaceutical Industries Co., Egypt) was used as an internal standard (IS). Sodium dodecyl sulphate (SDS) 99%, triethylamine (TEA) and orthophosphoric acid 85% (RiedeldeHäen, Sleeze, Germany) were also used. Ethanol, n-propanol and n-butanol (Sigma-Aldrich, Germany) were also utilized. Urine samples were obtained from a healthy volunteer (female, 40 years old).
Chromatographic conditions
In this study, a Spherisorb ODS-2, C18 column (150 mm × 4.6 mm i.d., 5 µm particle size; Teknokroma, Barcelona, Spain) was used. A hybrid micellar mobile phase consisting of 0.12 M SDS, 6% n-butanol and 0.3% TEA was prepared in 0.02 M orthophosphoric acid. The pH of the mobile phase was adjusted to pH 3.0. The mobile phase was filtered through a 0.45-µm Millipore membrane filter and sonicated for 30 min before use.
A time-programmed UV-detection technique was applied at 275 nm for the first 6 min and then at 405 nm to the end of the run. MTC was used as internal standard (IS).
Standard solutions
Stock solutions equivalent to 0.10 mg/mL of CIP, NOR and PHZ were prepared by dissolving 10.0 mg of each drug separately in 100 mL of methanol with the aid of an ultrasonic bath. Working standard solutions were prepared by appropriate dilution of the stock solutions with methanol. The prepared solutions were protected from light throughout the study (3) and were found to be stable for at least 7 days without alteration when kept in the refrigerator. Stock solution of MTC containing 0.40 mg/mL was prepared to be used as IS.
Procedures
Construction of the calibration graphs. The spectrophotometric method. Working standard solutions of CIP, NOR and PHZ were prepared from the previous stock solutions by serial dilutions with methanol to obtain final concentrations of 1.0-16.0 µg/mL for CIP or NOR and 1.0-10.0 µg/mL for PHZ (final concentration). The zero-order absorption spectra in methanol were recorded, and the absorbance was measured at 405 nm for determination of PHZ. Regarding CIP or NOR, the first derivative of the ratio spectra (the spectra of CIP or NOR divided by the spectrum of 6.0 µg/mL PHZ solution) were derived. The amplitudes at 267 or 287 nm for CIP and 268 or 291 nm for NOR were measured. The absorbance value for PHZ or derivative amplitudes (for CIP or NOR) were then plotted against the final concentrations of the studied drugs (µg/mL) to get the calibration graphs. Alternatively, the corresponding regression equations were derived.
The MLC method. Accurately measured aliquots of the stock solutions were transferred into a series of 10 mL volumetric flasks, so that the final concentrations were in the range of 0.5-20.0 µg/mL for CIP, NOR or PHZ. To each flask, 1 mL of MTC stock solution was added as IS so that its final concentration was 40.0 µg/mL. Then, the solutions were completed to the volume with the mobile phase and mixed well. Aliquots of 20 µL were injected (triplicate) and eluted with the mobile phase under the optimum chromatographic conditions. The average peak area ratio (drug/IS) versus the final concentration of the drug in µg/mL was plotted. Alternatively, the corresponding regression equations were derived.
Analysis of CIP or NOR/PHZ synthetic mixtures
Aliquots of CIP or NOR and PHZ standard solutions with the pharmaceutical ratio of 2.5:1 and 4:1 (w/w) were transferred into a series of 10 mL volumetric flasks. The procedures described under the "Construction of the calibration graphs" section were then applied. The percentage recoveries were calculated by referring to the calibration graphs, or using the corresponding regression equations.
Analysis of the studied drugs in their commercial single tablets Ten tablets (ciprocin ® 250, Epinor ® or Urisept ® ) were accurately weighed, finely pulverized and thoroughly mixed. Accurately weighed quantities of the pulverized tablets equivalent to 20.0 mg of the studied drugs were transferred into a 100-mL volumetric flask and ∼80 mL of methanol were added. The contents of the flasks were sonicated for 30 min, completed to the volume with the same solvent and filtered. Different aliquots from each filtrate containing suitable concentrations of the studied drug were analysed as described under the "Construction of the calibration graphs" section. The nominal contents were calculated either from previously plotted calibration graphs or using the corresponding regression equations.
Analysis of the studied drugs in their co-formulated tablets Accurately weighed quantities of the mixed contents of 10 finely powdered laboratory-prepared co-formulated tablets equivalent to 25.0 mg CIP or 40.0 mg NOR and 10.0 mg PHZ were transferred into 100 mL volumetric flasks and ∼80 mL of methanol were added to each flask. The contents of the flasks were sonicated for 30 min, completed to the volume with the same solvent and filtered. Different aliquots from each filtrate containing suitable concentrations of the studied drugs were taken and analysed as described under the "Construction of the calibration graphs" section. The nominal contents were calculated either from previously plotted calibration graphs or using the corresponding regression equations.
Analysis of the studied drugs in spiked human urine Aliquots of the human urine sample (1 mL) were transferred into a series of 10 mL volumetric flasks and spiked with increasing concentrations of the studied drugs (0.5-3.0 µg/mL). The volume was completed to the mark with the mobile phase, and the contents of the flasks were mixed well. The solutions were filtered through a 0.45-µm cellulose acetate syringe filter, and then 20 µL aliquots were injected (triplicate) and eluted with the mobile phase under the previously described chromatographic conditions. A blank experiment was carried out simultaneously. The average peak areas of the studied drugs were plotted versus the corresponding concentrations to get the calibration graphs, and the corresponding regression equations were derived.
Results
The spectrophotometric method
The zero-order absorption spectra of the studied drugs in methanol are greatly overlapped; PHZ could be directly determined in the presence of CIP or NOR at 405 nm. However, it is difficult to resolve either CIP or NOR in the presence of PHZ (Figure 2 ). Therefore, we resorted to ratio derivative spectrophotometry in an attempt to analyse these drugs. Figure 3A shows the ratio spectra of different concentrations of the CIP standard while Figure 3B shows their first derivatives. As it can be seen, the amplitudes at 267 nm ( 1 DD 267 ) and 287 nm ( 1 DD 287 ) in the ratio derivative spectra correspond to CIP present in the solution, so it can be used for its quantitative determination. Likewise, Figure 4A and B show the ratio spectra of different concentrations of NOR standard as well as the corresponding first derivative spectra, on the basis of which NOR can be quantified by measuring the amplitudes at 268 nm ( 1 DD 268 ) and 291 nm ( 1 DD 291 ).
For selecting the standard solution as divisor, different concentrations were tested and different calibration curves were obtained. The best results in terms of signal-to-noise ratio, sensitivity and repeatability were obtained by using the spectra of 6.0 µg/mL PHZ solution as divisor in the determination of both CIP and NOR.
MLC method
The proposed MLC method represents an environmentally nontoxic method for the separation and simultaneous determination Figure 2 . Zero-order absorption spectra of the studied drugs in methanol: (A) 10 µg/mL CIP, (B) 16 µg/mL NOR and (C) 4 µg/mL PHZ.
of CIP or NOR and PHZ in a reasonable time <10 min ( Figure 5 ). The retention times for MTC (IS), CIP or NOR and PHZ were 2.0, 4.0 or 3.8 and 8.4 min, respectively. It also permitted the quantitation of these drugs in their single and co-formulated tablets. By virtue of its high sensitivity, the proposed method was applied for the determination of the studied drugs in human urine with no need for sample pretreatment steps, where the solubilization capability of the micelles allows the direct injection of biological samples.
Discussion
Optimization of the chromatographic performance and system suitability Well-defined symmetrical peaks were obtained after thorough experimental trials that can be summarized as follows.
Choice of column Two columns were tested for performance investigation, which include Spherisorb ODS-2 column (150 mm × 4.6 mm i.d., 5 µm particle size; Teknokroma, Barcelona, Spain) and Promosil ODS 100 A column (250 × 4.6 mm i.d., 5 µm particle size; Agela Technologies, USA).
The experimental studies revealed that the first column was the more suitable because it produced symmetrical peaks with high resolution within a reasonable time. The second column was not suitable due to long unacceptable retention time, especially for PHZ.
Choice of appropriate wavelength
The absorption spectra of both CIP and NOR in methanol exhibit maximum absorption at 275 nm, so that this wavelength was selected as the optimum wavelength for their determination with reasonable sensitivity. The maximum absorbance for PHZ was attained at 405 nm. So, programmable UV detection was employed to the allow sensitive determination of these drugs in the recommended ratios. CIP or NOR was detected at 275 within the first 6 min, after that, PHZ could be detected at 405 nm until the end of the run.
Mobile phase composition
Several modifications in the mobile phase composition were performed in order to study the possibilities of improving the performance of the chromatographic system. These modifications included the change of the type and concentration of the organic modifier, the concentration of SDS and the pH. The results obtained are shown in Table I .
Type of co-surfactant. Different organic solvents including ethanol, n-propanol, n-butanol and n-pentanol were tried as modifiers. Among these solvents, only n-butanol could elute both drugs with adequate sensitivity within a reasonable time. Other modifiers either showed a broad peak with long unacceptable retention time for PHZ with a marked decrease in sensitivity (ethanol, and n-propanol) or resulted in a very high pressure of the pump (n-pentanol).
Concentration of co-surfactant
The effect of changing the % concentration of n-butanol on the chromatographic behaviours of the test solutes was investigated in the concentration ranges of 4-10%. As expected, the retention times of the studied drugs decreased upon increasing the ratio of n-butanol. A concentration of 6% of n-butanol was chosen as the optimal concentration where it provides a good combination of the peak shape, resolution factor and analysis time.
Concentration of SDS. SDS concentration was varied over the range of 0.08-0.14 M. Using the mobile phase containing 0.08 M SDS resulted in well-separated peaks of the studied drugs but with long unacceptable retention times and broad peaks. The retention times of the drugs decreased while the symmetry of their peaks increased as the molar concentration of SDS increased. The best compromise in terms of resolution, run time, efficiency and peak symmetry was achieved upon using a mobile phase containing 0.12 M SDS.
pH of the mobile phase. Upon changing the pH of the mobile phase over the range 3.0-6.0, it was found that decreasing the pH would increase the resolution factor, symmetry of the peaks and number of theoretical plates. No significant change in the retention times of the tested drugs was observed except only at pH 6, the retention time of PHZ decreased. This may be attributed to decreasing the protonated amino group concentration at higher pH and so the interaction and the affinity towards the anionic surfactant were decreased. Table I illustrates that pH 3.0 was the most appropriate one giving wellresolved symmetrical peaks, the highest number of theoretical plates and the lowest tailing factors.
Flow rate
The effect of the flow rate on the separation of peaks of the studied compounds was studied, and a flow rate of 1.0 mL/min was optimal for good separation in a reasonable time. A flow rate of 0.8 mL/min was not selected, although it gave the highest number of theoretical plates and the highest resolution factors due to unsuitability of the peak shape for measurement as well as the relatively high values of the tailing factor.
The nature of IS Different drugs were investigated for the choice of a suitable IS. These drugs include xipamide, indapamide, losartan potassium, propranolol HCl and MTC. MTC was found to be the best IS producing a wellresolved peak from the studied drugs and it was used in a concentration of 40 µg/mL, whereas, other investigated drugs resulted in overlapping peaks with CIP or NOR (xipamide, indapamide, losartan) or PHZ ( propranolol).
System suitability test parameters
To ascertain the reproducibility of the MLC method, system suitability tests were performed using the working standard solutions of the studied drugs. Resolution (R s ), theoretical plate number (N), relative retention (α) and tailing factor (T) were measured as the criteria for system suitability testing. These results are satisfactory compared with the minimum values necessary for an acceptable method. 
Method validation
To investigate the validity of the developed methods, they were tested linearity and range, limit of detection (LOD), limit of quantitation (LOQ), accuracy, precision, robustness, selectivity, stability of sample solution and mobile phase.
Linearity
Under the above-described experimental conditions, a linear relationship was established by plotting either the absorbance value, derivative amplitude or the peak area ratio [drug/IS] against the drug concentration in µg/mL for the spectrophotometric or the MLC method, respectively. The graphs were found to be rectilinear over the concentration ranges cited in Table II . Linear regression analysis of the data gave the below-mentioned equations. where ( 1 DD wavelength ) is the first derivative amplitude of the ratio spectra at the cited wavelength, A is the absorbance value and C is the concentration in µg/mL. where PA is the peak area ratio, C is the concentration of the drug in µg/mL and r is the correlation coefficient. Statistical analysis (33) of the data gave a high value of the correlation coefficient (r) of the regression equation, small values of the standard deviation of residuals (S y/x ), of intercept (S a ), and of slope (S b ) and small values of the percentage relative standard deviation (% RSD) and the percentage relative error (Table II) . These data proved low scattering of points around the calibration graphs.
Spectrophotometric method
MLC method
LOQ and LOD
The LOQ and LOD were calculated according to ICH Q2R1 recommendations (34) using the following equation:
where S a is the standard deviation of the intercept of the calibration curve and b is the slope of the calibration curve. The LOQ and LOD values for the studied drugs by the proposed methods are presented in Table II .
Accuracy
To prove the accuracy of the proposed methods, the results of the assay of the studied drugs were compared with those of the official method (3) . Statistical analysis of the results using Student's t-test and variance ratio F-test (33) revealed no significant difference between the performance of the two methods regarding the accuracy and precision, respectively. Furthermore, the good accuracy was proposed by the good values of the percentage recoveries together with the small values of the percentage relative error, %Er < 2%.
All the studied drugs were assayed using the HPLC method recommended in the official USP method (3) for the assay of PHZ in its tablets. Chromatographic separation was achieved using a L1 column with a mobile phase consisting of 0.02 M dibasic ammonium 
Precision
The intra-day precision was evaluated through replicate analysis of different concentrations of the studied drugs in pure forms within the specific working concentration ranges. Each sample was analysed three successive times. Similarly, the inter-day precision was evaluated through replicate analysis of the three different concentrations on three successive days. The results obtained are summarized in Table III . The RSDs were found to be very small indicating reasonable repeatability and intermediate precision of the proposed methods.
Robustness
The robustness of the spectrophotometric method was investigated by analysing data after checking four variables. The variables were methanol volume (9.5 ± 0.5 mL), wavelength (±1 nm), scan speed (slow and fast) and sonication time. The peak amplitude or the absorbance of the studied drugs was not greatly affected by these changes (Table IV) . The robustness of the MLC method was also evaluated by the constancy of the peak area ratio with the deliberated changes in the experimental parameters; these parameters include n-butanol concentration (6 ± 0.2% (v/v)), concentration of SDS (0.12 M ± 0.01) and pH of the mobile phase (3 ± 0.2). These minor changes did not greatly affect the peak area ratios of the studied drugs (Table IV) .
Selectivity
The selectivity of the spectrophotometric method was investigated by observing any interference encountered from common tablet excipients. It was shown that these compounds did not interfere with the results of the proposed method.
Furthermore, the selectivity of the MLC method was assessed by carrying out the chromatographic procedure on different lots of blank urine samples after dilution with the mobile phase. No interfering peaks were detected at the retention times of the analytes, indicating no interference from the endogenous substances ( Figure 6 ). The stability of the column was not affected by the injection of urine samples. Both resolution and the retention times of the drug peaks remained constant over 3 weeks of work. In addition, spectral purities of CIP, NOR and PHZ chromatographic peaks analysed whether in urine or tablet sample solutions were evaluated using the UV spectra. The purity angle was within the purity threshold limit in all of the analysed samples, indicating that no additional peaks were co-eluted with each of the analyte evidencing the ability of the method to assess the analytes of interest in urine or tablets without any interference from endogenous components of the urine or co-formulated adjuvants.
Stability of standard solutions and mobile phase
The stability of the stock solutions was determined by quantitation of the studied drugs and comparing the results to freshly prepared solutions. It was found that no significant change was observed in standard solutions response, relative to freshly prepared standards. Similarly, the stability of the mobile phase was checked. The results obtained in both cases proved that the samples solutions ( protected from light) and mobile phase used during the assay were stable up to 7 and 3 days, respectively, when kept in the refrigerator at 4°C.
Applications
Analysis of CIP/PHZ or NOR/PHZ synthetic mixtures; single and co-formulated tablets
The proposed methods were applied to the simultaneous determination of CIP or NOR and PHZ in synthetic mixtures that medicinally recommended in a ratio of 2.5:1 or 4:1 (w/w), respectively, as in tablets (Table V) .
Furthermore, the proposed methods were successfully applied to the determination of the studied drugs in their single and co-formulated tablets (Tables VI and VII) . The results shown in Tables VI and VII are in good agreement with those obtained using the official methods (3). Statistical analysis of the results obtained using Student's t-test and variance ratio F-test (33) revealed no significant difference between the performance of the methods regarding the accuracy and precision, respectively.
Application of the MLC method to the determination of the studied drugs in human urine
It is well known that urine samples contain a large amount of protein which in turn could seriously damage the packing material of column and shorten its life. Moreover, the broad urine peak could hinder the detection of the studied drugs. In our MLC method, the solubilizing power of micelles permit the biological assessment of the analytes after simple dilution with the eco-friendly micellar mobile phase and protect the stationary phase from precipitation of protein and other endogenous compounds on its surface. In bioavailability study of analytes (mostly excreted in the urine un metabolized), it is much better to detect the drug in urine sample rather than in blood samples as it is a Figure 6 . Application of the proposed method for the determination of the studied drugs in spiked human urine: (A) CIP (2 µg/mL), PHZ (2 µg/mL) and (B) NOR (2 µg/mL), PHZ (2 µg/mL). CIP, ciprofloxacin HCl; NOR, norfloxacin; PHZ, phenazopyridine HCl. non-invasive technique and collection of a large volume of urine is more easier (35) . Figure 6 represents typical chromatograms for spiked urine samples for the studied drugs using the MLC method. No interference is observed, and the drugs peaks are well separated from the protein band. Table VIII represents the results of determination in spiked human urine. The obtained results are promising that it can be applied for the determination of the studied drugs in real urine samples following their ingestion.
Under the above-described experimental conditions, a linear relationship was established by plotting the peak area against the drug concentration. Linear regression analysis of the data gave the following equations: where P is the peak area, C is the concentration of the drug in µg/mL and r is the correlation coefficient. The %RSD was usually <4.5% in the spiked urine (36) , indicating high precision of the MLC method. In addition, good accuracy was obtained because the maximum deviation from the nominal concentration fulfils the requirements for bioassays and is suitable for our purpose (36) .
Conclusion
The proposed methods for the simultaneous determination of CIP or NOR and PHZ were shown to be reliable, simple, accurate and precise. In addition, they could be applied to the analysis of the studied drugs in co-formulated tablets. The good validation criteria of the proposed methods allow their use in quality control laboratories. The MLC method also offers the possibility to determine the studied drugs in spiked human urine without prior protein precipitation and eliminating other interfering substances, thus considerably reducing the cost and analysis time. In addition, the use of micellar mobile phases reduces the consumption of organic solvents and thus meets the requirement of "green chemistry" concept. 
